According to Zhitong Finance App, Xintai Healthcare (02291.HK) announced that on August 21, 2026, the company, the seller (Lepu (Beijing) Medical Devices Co., Ltd.) and Shanghai Minwei Biotechnology Co., Ltd. (target company) signed a share transfer agreement. According to this, the company conditionally agreed to the acquisition, and the seller conditionally agreed to sell a total of 54.2384% of the target company's shares at a cost of RMB 1,088 billion in cash.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.